Summary: Some investigators argue that treating epi lepsy with several antiepileptic drugs (AEDs) simulta neously (polytherapy) may give rise to more adverse ef fects than monotherapy, but this argument lacks support ing quantitative data, To reexamine this issue, we recruited a cohort of patients from the outpatients of the Special Centres for Epilepsy in The Netherlands and from the outpatients of the Department of Neurology, Nij megen University, The Netherlands. Two tools were used for analysis. All daily doses of antiepileptic drugs (AEDs) were standardized by the ratio of prescribed daily dose to defined daily dose (PDD/DDD). The DDD is the assumed average effective daily dose for a drug used for its main indication in adults. The assignment of DDD val ues is the task of the World Health Organization (WHO) Collaborating Centre for Drugs Statistics Methodology and Nordic Council on Medicines, which regularly pub lishes Guidelines for Defined Dally Doses. The severity of adverse effects (AE) was assessed by using the Neu rotoxicity Index and the Systemic Toxicity Index as de veloped by the VA Cooperative Study Group for their recent studies comparing the efficacy and tolerability of AEDs. One hundred sixty-one patients received mono therapy; all had a PDD/DDD ratio ^2/day; 128 of 262 patients receiving poly therapy also had ^2 PDD/DDD ratios/day. The mono-and poly therapy groups were stratified according to the PDD/DDD ratio. The prevalence of neurological AE for patients with similar PDD/DDD ra tios was 50-80% for monotherapy patients and 50-82% for poly therapy patients. The difference between the mono-and polytherapy groups was not significant. The prevalence of neurological AE for patients receiving poly therapy with a PDD/DDD ratio > 2 .0 was 71-100%, whereas all patients with a PDD/DDD ratio > 4.0 had neu rological AE. This difference between patients with a PDD/DDD ratio ^2.0 and those with > 2.0 was statisti cally significant; p < 0.05. The severity of neurological AE also increased with dose, but appeared to peak at -3.5 PDD/DDD ratio. Our study underscores the useful ness of applying quantitative methods to the analysis of drug AE, Comparison of monotherapy and polytherapy showed no difference for equipotent doses. Because dis tribution of the AED doses was uneven between the groups receiving mono-and poly therapy, our study per mits only a tentative statement that the frequency and severity of AE is independent of the use of either. In addition, frequency and intensity of AE apparently are not very sensitive to changes in dose. An experimental prospective study is planned to verify or refute the con clusions of this observational pilot study. Key Words: Ep ilepsy-Antiepileptic drugs-Adverse effectsMonotherapy-Polytherapy-Clinimetrics.
chronic toxicity, (b) exacerbation of seizures, and (c) drug interactions. The evidence lacks quantita tive support, however.
A few years ago, three special centers for epi lepsy in The Netherlands and the subdepartment of Epileptology of Nijmegen University decided to de termine whether further quantification of symptoms and signs could improve optimal management of ep ilepsy. Feinstein (6) has been a strong advocate of quantification. He recommends the use of the term clinimetric indices as the term for the rating scales that have been developed for clinical phenomena. To advance these studies of the feasibility and prof itability of using quantitative data, we examined
MONO-OR POLYTHERAPY FOR EPILEPSY 441
whether the incidence and/or severity of AE was affected by the use of one AED (monotherapy) or several AEDs (polytherapy) to control seizures.
USE OF DEFINED DAILY DOSES (DDD)
We hypothesized that there should be no differ ence in either the frequency or the severity of AE if equipotent doses of AEDs are used. To compare the effect of one drug with the effect of a combina tion of several drugs a measure of equipotency must be determined. Therefore, all daily doses were stan dardized by using the ratio of prescribed daily dose to DDD (PDD/DDD). The PDD is the dose pre scribed by the physician for the individual patient and because only compliant patients were admitted to the study the PDD equals the actual daily dose. The DDD is the assumed average effective daily dose for the drug used for its main indication in adults and is expressed in amount of the active sub stance. DDD the average maintenance dose of a particular drug for its main indication in adults. According to DDD methodology of the WHO, half of a DDD of AED-I plus half of a DDD of AED-II should be as effective as a full dose of either, e.g., 750 mg valproate (VP A) plus 500 mg carbamazepine (CBZ) should be as ef fective as 1,500 mg VPA or 1,000 mg CBZ.
Because we were interested only in comparing AE in monotherapy and poly therapy, efficacy of monotherapy and polytherapy was not assessed in this study. Efficacy would be related to the severity of the epilepsy. There is no a priori reason to expect that sensitivity to toxic effects of AEDs is related to the severity of the epilepsy. 
QUANTIFICATION OF AE

MATERIALS AND METHODS
Population
The Netherlands is exceptional in that it has a long tradition of tertiary care. Three special centers provide both intramural and extramural tertiary care nationwide for persons with difficult-to-treat epilepsies. The country has a national network of 16 outpatient clinics associated with these centers (ap proximately one clinic for each 1 million inhabit ants). Patients attending these clinics are always ex amined by the same physician, and there is a high level of compliance.
For the present study, the data on medication and AE recorded at the first assessment of the patients recruited in the years 1991 through 1993 for previ ous studies of the use of quantitative data (10-12) were collected in to to. All patients were either at tending an outpatient clinic of one of the special centres for epilepsy or of a university hospital neu rology department. The study was approved by the ethical committees of the participating institutes: Patients aged ^15 years whose seizures could be defined accurately according to the International Classification of the International League Against Epilepsy (ILAE) were included in the study. Pa tients with factors that were believed to complicate the evaluation of whether a clinimetric approach » has added value over present patient management were excluded from the study; these factors in cluded progressive brain disorders, obvious noncompliance in drug usage or seizure registration, pseudoseizures, and severe mental retardation.
Indexes
The Indexes used in this study were first de scribed by Cramer et al. (13) Table 2 ). The Composite Index of Impairments (CII) is the sum of the SA and toxicity ratings. Patient data collection Before the start of the study, patients meeting the inclusion criteria were informed about the purpose and the procedure of the study and asked to collab orate. None refused. On the day of their regular visit the patients were interviewed and examined for -30 min by the investigator to obtain data nec essary to determine the value of the indexes. Data from all patients receiving monotherapy (n = 161) and also from patients receiving polytherapy with a PDD/DDD ratio in the same range (n = 128) were examined. Therefore, 289 patients entered the main arm of the study; the maximum PDD/DDD ratio was 2.0. All patients with a PDD/DDD ratio >2.0 (n = 134) were in the poly therapy group. The poly therapy group as a whole (n = 262) was also studied separately in comparisons of patients receiving poly therapy with a PDD/DDD ratio of ^2.0 and >2.0. The patients were stratified according to the PDD/DDD ratio with intervals of 0.33 PDD/DDD ratio and the prevalence and severity (NTX, STX) of AE was studied in each stratum (Tables 3 and 4) . Although serum levels of AEDs were available, they were not included in this study because AE might be due to metabolites, the entire spectrum of which was not measurable.
Statistical analysis
Because of the size of the strata, Fisher's exact test (two-tailed) was applied for the assessment of differences in gender, for the study of the overall prevalence of AE, and for the prevalence per stra tum of PDD/DDD ratios. The Kruskal-Wallis test was used for the assessment of differences in the severity of AE. Differences were considered statis tically significant at p < 0.05. Multiple-regression analysis was used to investigate whether gender, age, duration of epilepsy, or the use of either monoor polytherapy in themselves or combined could ex plain the variance in outcome of the toxicity scores. However, no factor reached significance.
RESULTS
Population
Of 289 patients entering the main study, 124 were men (43%) and 165 were women (57%). No statis tically significant difference was noted in the gender distribution between patients receiving monother apy and those receiving polytherapy with a PDD/ DDD ratio ^2.0.
The mean age of the patients receiving monother apy was 37 years (range 15-76 years); that of pa tients receiving poly therapy was 43 years (range 15-75 years). This difference in mean ages between 
Number of AEDs prescribed in polytherapy
The distribution of the number of AEDs over the various PDD/DDD ratios for all patients is shown in Table 5 . Sufficient numbers were available in only two classes to allow comparison of the neurotoxic and systemic toxic effects according to the number of drugs used in polytherapy. Respectively, 38 pa tients with a PDD/DDD ratio of 1.67-2.00 used two drugs and 10 patients used three drugs, whereas 11 patients with a PDD/DDD ratio of 2.34-2.66 used two drugs and 14 patients used three drugs.
AE prevalence and severity
Overall, no significant differences in'the preva lence of AE was noted between patients receiving monotherapy and polytherapy who had similar PDD/DDD ratios (Tables 3 and 4) . Separate deter minations of neurotoxicity and systemic toxicity did not change that finding. When specific AE were considered, the only significant differences in prev alence were sedation (37% in those receiving mono therapy and 52% in those receiving polytherapy, p < 0.05) and cognitive impairment (27% in those re ceiving monotherapy and 34% in those receiving polytherapy, p < 0.05) ( Table 6 ). In both groups, sedation was the most common AE. The prevalence of individual systemic AE did not differ between the groups.
Neither the cumulated scores nor the median scores for intensity of each specific AE differed sig nificantly between patients treated with monother apy and those treated with poly therapy. Neither did the distribution of the severity scores for the AE separately differ between patients treated with monotherapy and those treated with poly therapy.
AE prevalence and severity for PDD/DDD ratio >2.0
The prevalence of AE in patients receiving poly therapy with a PDD/DDD ratio >2.0 was greater than that in patients receiving polytherapy with a PDD/DDD ratio =^2.0: 91 and 78%, respectively. This difference was statistically significant (p < 0.05), The prevalence of neurological AE effects showed some increase with higher doses of AEDs, although this finding was not statistically signifi- cant. The severity of neurological AE also in creased with higher doses, but appeared to peak at a PDD/DDD ratio level of 3.67-4.00 (Table 7) .
AE and number of AEDs No statistically significant difference was noted between the patients receiving two AEDs and three
AEDs with respect to the prevalence and severity of neurological AE. Systemic AE occurred more frequently in the patients using three AEDs, al though the severity did not differ. 
DISCUSSION
Possible confounders
The data from our patients have been standard ized in two respects. AE of AEDs were assessed quantitatively with respect to both the prevalence of the AE and their severity. The scores are pre sumed to be independent of the type of the drug responsible. The AED doses were standardized by the PDD/DDD ratio. The concept of adding frac tions of the DDD as a measure of drug exposure obviously does not take into account linearity of dose-effect relationships of metabolic or dynamic interactions of the drugs in individuals, but the con cept has been used extensively in pharmacoepidemiological studies (16).
Because our study is a prospective observational study, it has an inherent weakness: The parameters could not be set according to the demands of the study. All patients visiting the outpatient clinic who met the entry criteria were studied. The patients receiving monotherapy and those receiving poly therapy did not differ with respect to gender but differed significantly with respect to mean age and mean duration of epilepsy. Patients receiving mono therapy were on the average, younger and had had epilepsy for a shorter time. Whether this difference influences the occurrence of AE cannot be judged from our study. When the results were assessed by multiple-regression analysis, age and duration did not explain the variance in frequency and severity of AE. The patients treated with poly therapy with a PDD/DDD ratio ^2.0 and those with a PDD/DDD ratio >2.0 did not differ significantly either in gen der, age, or duration of epilepsy.
In the main arm of the study (n = 289), 71% of patients receiving monotherapy and 79% receiving poly therapy had AE. This result from a prospective study contrasts with the results obtained in a retro spective study (9) Comparison of patients receiving monotherapy and those receiving polytherapy with similar PDD/ DDD ratios showed no overall difference in either prevalence or severity of neurological and systemic AE. It is remarkable that on stratification neither the frequency nor the severity increased notably per stratum, although they tended toward increase. Because ours was an observational study, our re sults may well reflect the practice not to increase dose beyond a tolerable level. The dose tolerated may differ from person to person, however. Anal ysis of the data of patients receiving polytherapy showed an increase in frequency of AE to 100% when the PDD/DDD ratio increased to > 3.0. The severity of AE increased at a PDD/DDD ratio of 3.67-4.00, followed by a decrease at higher doses. We attribute this to the practice of administering such high doses only to patients who are relatively insensitive to AE. Patients receiving poly therapy had a significantly longer duration of epilepsy, which may have led to the development of tolerance to some AE, and thus to a lower prevalence and 
Abbreviations as in Tables 1,3 , and 4.
severity. This possibility could not be confirmed in the context of this study and will require further investigation.
Lack of correlation
The prevalence of AE in the group receiving polytherapy (n = 262) was greater for patients with a PDD/DDD ratio of >2.0. No correlation was noted between the number of AEDs and prevalence of neurological AE which again suggests that the occurrence and the severity of AE are influenced by the total dose and not by the number of AEDs pre scribed. Keyser et al. (17) showed that patients treated with polytherapy had a higher prevalence of AE than did patients treated with monotherapy. In that study, all patients were compared, irrespective of the dose of medication, in contrast to the patients in the main arm of the present study in which only patients with similar PDD/DDD ratios were com pared.
Sedation and cognitive impairment were the two more frequent neurological AE in patients receiving polytherapy. However, there was no difference in the intensity (median level of NTX score) of these AE between the two groups. There is no primafacie explanation for this finding, which obviously re quires further study.
Our results underscore the feasibility of applying clinimetric methods to the analysis of AE of drugs. Frequency and intensity of AE apparently are not very sensitive to changes in dose. Neither was any difference noted between monotherapy and poly therapy. Because the distribution of the dose of AEDs was uneven between the groups receiving mono-and polytherapy, our study permits only a tentative conclusion that the frequency and severity of AE is independent of the use of either. Longer duration of epilepsy in the cohort on polytherapy, might be supposed a complicating factor but this possibility was not confirmed by the statistical anal ysis. An experimental study is planned to verify or refute the conclusions of this observational study,
